MRI Findings of Intracranial Hemorrhages in ARCADIA-MRI: An Ancillary Study to the ARCADIA Trial.

ABSTRACT:

Background and purpose

The ARCADIA-MRI study, an ancillary study to the randomized Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial, reported that the risk of incident nonlacunar covert infarcts was lower in the apixaban group than in the aspirin group. This article presents the additional, prespecified, exploratory outcomes beyond the primary article, specifically examining the effect of apixaban on hemorrhagic lesions on MRI.

Materials and methods

The ARCADIA-MRI study was conducted in conjunction with ARCADIA trial visits, with follow-up durations ranging from 4 months to 5.3 years (median, 27 months). It included randomized patients who were eligible for cognitive testing and lacked MRI contraindications. Two experienced

SUBMITTER: Chen H 

PROVIDER: S-EPMC12549002 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature